Abstract
The immunopathology of rheumatoid arthritis (RA) is now better understood, and this knowledge has been translated into more effective therapy with biologic response modifiers. The first group of biologic response modifiers are the tumor necrosis factor inhibitors. There efficacy in controlling RA has been such that remission is now the goal of RA management. As with any patient treatment, safety is an issue; patients will need ongoing monitoring for infections, tumors, and other rare complications.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 709-715 |
| Number of pages | 7 |
| Journal | Annals of the New York Academy of Sciences |
| Volume | 1051 |
| DOIs | |
| State | Published - 2005 |
Fingerprint
Keywords
- Biologic response modifiers
- Corticosteroids
- Disease-modifying antirheumatic drugs
- DMARDs
- Rheumatoid arthritis
- TNF-α inhibitors
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
Cite this
Tumor necrosis factor inhibitor therapy for rheumatoid arthritis. / Naguwa, Stanley M.
In: Annals of the New York Academy of Sciences, Vol. 1051, 2005, p. 709-715.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Tumor necrosis factor inhibitor therapy for rheumatoid arthritis
AU - Naguwa, Stanley M
PY - 2005
Y1 - 2005
N2 - The immunopathology of rheumatoid arthritis (RA) is now better understood, and this knowledge has been translated into more effective therapy with biologic response modifiers. The first group of biologic response modifiers are the tumor necrosis factor inhibitors. There efficacy in controlling RA has been such that remission is now the goal of RA management. As with any patient treatment, safety is an issue; patients will need ongoing monitoring for infections, tumors, and other rare complications.
AB - The immunopathology of rheumatoid arthritis (RA) is now better understood, and this knowledge has been translated into more effective therapy with biologic response modifiers. The first group of biologic response modifiers are the tumor necrosis factor inhibitors. There efficacy in controlling RA has been such that remission is now the goal of RA management. As with any patient treatment, safety is an issue; patients will need ongoing monitoring for infections, tumors, and other rare complications.
KW - Biologic response modifiers
KW - Corticosteroids
KW - Disease-modifying antirheumatic drugs
KW - DMARDs
KW - Rheumatoid arthritis
KW - TNF-α inhibitors
UR - http://www.scopus.com/inward/record.url?scp=25444482353&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=25444482353&partnerID=8YFLogxK
U2 - 10.1196/annals.1361.115
DO - 10.1196/annals.1361.115
M3 - Article
C2 - 16127011
AN - SCOPUS:25444482353
VL - 1051
SP - 709
EP - 715
JO - Annals of the New York Academy of Sciences
JF - Annals of the New York Academy of Sciences
SN - 0077-8923
ER -